Erectile Dysfunction (ED) Drugs Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Jun 2018| TMR653A| Transparency

Report Highlights

Erectile Dysfunction (ED) Drugs Market - Overview
This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile dysfunction, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global erectile dysfunction drugs market with respect to the leading segments based on drug class, distribution channel, and region.

The global erectile dysfunction drugs market has been segmented based on drug, distribution channel, and region. In terms of drug, the market has been classified into Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and others. Based on distribution channel, the global erectile dysfunction drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of erectile dysfunction. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the global erectile dysfunction drugs market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global erectile dysfunction drugs market.

Geographically, the global erectile dysfunction drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global erectile dysfunction drugs market.

Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global erectile dysfunction drugs market has been segmented as follows:

Global Erectile Dysfunction Drugs Market, By Drug
Viagra
Cialis
Staxyn/Levitra
Stendra/Spedra
Others

Global Erectile Dysfunction Drugs Market, By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Erectile Dysfunction Drugs Market, By Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa

  • Table 1 : Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 2 : Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 3 : Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2016–2026
  • Table 4 : North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2016–2026
  • Table 5 : North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 6 : North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 7 : Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 8 : Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 9 : Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 10 : Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 11 : Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 12 : Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 13 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 14 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 15 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 16 : Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 17 : Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
  • Table 18 : Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 19 : Pfizer, Inc. Products Offered
  • Table 20 : Pfizer, Inc. Recent Developments
  • Table 21 : Dong-A ST Co., Ltd. Products Offered
  • Table 22 : Dong-A ST Co., Ltd. Recent Developments
  • Table 23 : Eli Lilly and Company Products Offered
  • Table 24 : Eli Lilly and Company Recent Developments
  • Table 25 : Bayer AG Products Offered
  • Table 26 : Bayer AG Recent Developments
  • Table 27 : VIVUS, INC. Ltd. Products Offered
  • Table 28 : VIVUS, INC. Recent Developments
  • Table 29 : SK chemicals Products Offered
  • Table 30 : SK chemicals Recent Developments
  • Table 31 : Meda Pharmaceuticals Inc. Products Offered
  • Table 32 : Meda Pharmaceuticals Inc. Recent Developments
  • Table 33 : Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
  • Table 34 : Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
  • Table 35 : Apricus Biosciences, Inc. Products Offered
  • Table 36 : Apricus Biosciences, Inc. Recent Developments
  • Table 37 : Teva Pharmaceutical Industries Ltd. Products Offered
  • Figure 1 : Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2016–2026
  • Figure 2 : Market Value Share, by Drug Class (2017)
  • Figure 3 : Market Value Share, by Distribution Channel (2017)
  • Figure 4 : Market Value Share, by Region (2017)
  • Figure 5 : Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 6 : Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2016–2026
  • Figure 7 : Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2016–2026
  • Figure 8 : Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2016–2026
  • Figure 9 : Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2016–2026
  • Figure 10 : Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2016–2026
  • Figure 11 : Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2017 and 2026
  • Figure 12 : Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016–2026
  • Figure 13 : Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016–2026
  • Figure 14 : Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2016-2026
  • Figure 15 : Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 16 : North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2026
  • Figure 17 : North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 18 : North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 19 : North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2026
  • Figure 20 : Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
  • Figure 21 : Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 22 : Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 23 : Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 24 : Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
  • Figure 25 : Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 26 : Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 27 : Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 28 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
  • Figure 29 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 30 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 31 : Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 32 : Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018–2026
  • Figure 33 : Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 34 : Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 35 : Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 36 : Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2017)
  • Figure 37 : Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
  • Figure 38 : Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 39 : Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 40 : Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment
  • Figure 41 : Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
  • Figure 42 : Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 43 : Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 44 : Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 45 : Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 46 : Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2016
  • Figure 47 : Bayer AG Breakdown of Net Sales, by Region, 2017
  • Figure 48 : Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
  • Figure 49 : Bayer AG R&D Intensity and Net Income (US$ Mn) – Company Level, 2016–2017
  • Figure 50 : VIVUS, INC. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 51 : VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2017
  • Figure 52 : VIVUS, INC. Breakdown of Research and Development Expenses, 2017
  • Figure 53 : SK chemicals Consolidated Balance Sheet (US$ Bn), 2016
  • Figure 54 : SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2017
  • Figure 55 : SK chemicals R&D Intensity and Net Income (US$ Mn) – Company Level, 2014–2016
  • Figure 56 : Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2015
  • Figure 57 : Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2011–2015
  • Figure 58 : Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) – Company Level, 2014–2015
  • Figure 59 : Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 60 : Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
  • Figure 61 : Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) – Company Level, 2015–2016
  • Figure 62 : Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 63 : Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
  • Figure 64 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
  • Figure 65 : Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report